Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

EPM2A Antikörper (AA 244-331)

EPM2A Reaktivität: Human ELISA, IHC Wirt: Kaninchen Polyclonal unconjugated
Produktnummer ABIN7157845
  • Target Alle EPM2A Antikörper anzeigen
    EPM2A (Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A))
    Bindungsspezifität
    • 10
    • 8
    • 8
    • 6
    • 5
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 244-331
    Reaktivität
    • 43
    • 8
    • 7
    • 5
    • 4
    • 3
    • 3
    • 2
    • 1
    Human
    Wirt
    • 33
    • 9
    • 2
    Kaninchen
    Klonalität
    • 37
    • 7
    Polyklonal
    Konjugat
    • 29
    • 4
    • 4
    • 3
    • 2
    • 2
    Dieser EPM2A Antikörper ist unkonjugiert
    Applikation
    • 33
    • 25
    • 22
    • 6
    • 4
    • 4
    • 3
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    ELISA, Immunohistochemistry (IHC)
    Kreuzreaktivität
    Human
    Aufreinigung
    Antigen Affinity Purified
    Immunogen
    Recombinant Human Laforin protein (244-331AA)
    Isotyp
    IgG
    Top Product
    Discover our top product EPM2A Primärantikörper
  • Applikationshinweise
    Recommended dilution: IHC:1:20-1:200,
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Buffer
    PBS with 0.02 % sodium azide, 50 % glycerol, pH 7.3.
    Konservierungsmittel
    Sodium azide
    Vorsichtsmaßnahmen
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    -20 °C,-80 °C
    Informationen zur Lagerung
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • Target
    EPM2A (Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A))
    Andere Bezeichnung
    EPM2A (EPM2A Produkte)
    Synonyme
    TG-B antikoerper, Tg(TcraK,TcrbK)TG-BFlv antikoerper, EPM2 antikoerper, MELF antikoerper, laforin antikoerper, EPM2A, laforin glucan phosphatase antikoerper, epilepsy, progressive myoclonic epilepsy, type 2 gene alpha antikoerper, EPM2A antikoerper, Epm2a antikoerper
    Hintergrund

    Background: Has both dual-specificity protein phosphatase and glucan phosphatase activities. Together with the E3 ubiquitin ligase NHLRC1/malin, appears to be involved in the clearance of toxic polyglucosan and protein aggregates via multiple pathways. Dephosphorylates phosphotyrosine, phosphoserine and phosphothreonine substrates in vitro. Has also been shown to dephosphorylate MAPT. Shows strong phosphatase activity towards complex carbohydrates in vitro, avoiding glycogen hyperphosphorylation which is associated with reduced branching and formation of insoluble aggregates. Forms a complex with NHLRC1/malin and HSP70, which suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system (UPS). Acts as a scaffold protein to facilitate PPP1R3C/PTG ubiquitination by NHLRC1/malin. Also promotes proteasome-independent protein degradation through the macroautophagy pathway. Isoform 2, an inactive phosphatase, could function as a dominant-negative regulator for the phosphatase activity of isoform 1.

    Aliases: Epilepsy progressive myoclonus type 2 Lafora disease (laforin) antibody, Epilepsy progressive myoclonus type 2A Lafora disease (laforin) antibody, EPM2 antibody, Epm2a antibody, Epm2a gene antibody, EPM2A_HUMAN antibody, Lafora PTPase antibody, Laforin antibody, LAFPTPase antibody, LD antibody, LDE antibody, MELF antibody, RP3-466P17.2 antibody

    UniProt
    O95278
    Pathways
    Cellular Glucan Metabolic Process
Sie sind hier: